Dogwood Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dogwood Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $10 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 3,957% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-274.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in United States.
Cash Cushion Ratio
+17%Cash, after subtracting all debt, equals 17% of its market value (net cash).
Higher than 59% of Healthcare companies in United States.
Tangible Assets Ratio
10%Of every $100 the company owns, $10 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than almost all Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 75% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Dogwood Therapeutics, Inc. owes $0.15 for every $1 it owns. Dogwood Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.5Investors pay $0.5 for every $1 of Dogwood Therapeutics, Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
P/B ratio
0.56The share price is 0.56 times Dogwood Therapeutics, Inc.'s book value per share, lower than 90% of Healthcare companies in United States.
Market cap
$38 MThe total market value of all of Dogwood Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$68 MWhat Dogwood Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.01Net worth divided by the number of shares. The share price of $1.12 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-47.8%Dogwood Therapeutics, Inc. lost 47.8% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
Owes vs Owns
0.15×Dogwood Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneDogwood Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossDogwood Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashDogwood Therapeutics, Inc. held $6 M more cash than debt (net cash) at Dec 2025.
Questions
What is Dogwood Therapeutics, Inc.'s P/E ratio?
Investors pay $0.5 for every $1 of Dogwood Therapeutics, Inc.'s yearly profit, lower than 93% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dogwood Therapeutics, Inc.: $38 M ÷ $68 M (30 Jun 2026) = 0.6.
What is Dogwood Therapeutics, Inc.'s return on equity?
Dogwood Therapeutics, Inc. lost 47.8% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
How much does Dogwood Therapeutics, Inc. owe compared with what it owns?
Dogwood Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does Dogwood Therapeutics, Inc. pay a dividend?
No. Dogwood Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.